Sugauchi Fuminaka, Wang Richard Y-H, Qiu Qi, Jin Bo, Alter Harvey J, Shih J Wai-Kuo
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
J Infect Dis. 2006 Feb 15;193(4):563-72. doi: 10.1086/499823. Epub 2006 Jan 11.
A prophylactic vaccine for hepatitis C virus (HCV) requires generation of strong humoral as well as CD4(+) and CD8(+) T cell responses.
The immunomodulatory effects of the combination of 2 adjuvants, synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs emulsified with Montanide ISA720 (M-ISA720/CpG), were investigated using the murine model.
Administration of recombinant HCV (rHCV) nonstructural (NS) 3 and NS5B proteins plus M-ISA720/CpG (hereafter, "M-ISA720/CpG/rHCV protein") induced high anti-NS3 and anti-NS5B immunoglobulin (Ig) G titers, with the IgG2a isotype being predominant. NS3- and NS5B-specific interferon (IFN)- gamma - and interleukin-2-producing CD4(+) T cell responses, as assessed by enzyme-linked immunospot assay, were significantly more vigorous in mice immunized with M-ISA720/CpG/rHCV protein than in control mice immunized without adjuvant. NS3- and NS5B-specific IFN- gamma -producing CD8(+) T cell percentages, as measured by direct ex vivo intracellular cytokine staining assay, were, respectively, a mean+/-SD of 0.14% +/- 0.04% and 0.15% +/- 0.05% in mice immunized with M-ISA720/CpG/rHCV protein. Furthermore, boosting with recombinant NS3 expression plasmid DNA after priming with M-ISA720/CpG-adjuvanted rNS3 strikingly enhanced both CD4(+) and CD8(+) T cell responses.
Immunization with M-ISA720/CpG/rHCV protein is capable of inducing potent humoral as well as HCV-specific T helper type 1-biased CD4(+) and CD8(+) T cell responses. A DNA boost after a protein prime--a reversal of the conventional approach--may provide an alternative path to the development of an effective HCV vaccine.
丙型肝炎病毒(HCV)预防性疫苗需要产生强烈的体液免疫以及CD4(+)和CD8(+) T细胞应答。
使用小鼠模型研究了两种佐剂组合的免疫调节作用,即含有免疫刺激性胞嘧啶-鸟嘌呤二核苷酸基序的合成寡脱氧核苷酸与Montanide ISA720(M-ISA720/CpG)乳化。
给予重组HCV(rHCV)非结构(NS)3和NS5B蛋白加M-ISA720/CpG(以下简称“M-ISA720/CpG/rHCV蛋白”)诱导了高抗NS3和抗NS5B免疫球蛋白(Ig)G滴度,其中IgG2a亚型占主导。通过酶联免疫斑点试验评估,在用M-ISA720/CpG/rHCV蛋白免疫的小鼠中,NS3和NS5B特异性干扰素(IFN)-γ和产生白细胞介素-2的CD4(+) T细胞应答明显比未用佐剂免疫的对照小鼠更强烈。通过直接体外细胞内细胞因子染色试验测量,在用M-ISA720/CpG/rHCV蛋白免疫的小鼠中,NS3和NS5B特异性产生IFN-γ的CD8(+) T细胞百分比分别为平均±标准差0.14%±0.04%和0.15%±0.05%。此外,在用M-ISA720/CpG佐剂化的rNS3进行初次免疫后,用重组NS3表达质粒DNA进行加强免疫显著增强了CD4(+)和CD8(+) T细胞应答。
用M-ISA720/CpG/rHCV蛋白免疫能够诱导强大的体液免疫以及HCV特异性1型辅助性T细胞偏向的CD4(+)和CD8(+) T细胞应答。蛋白初免后进行DNA加强免疫——与传统方法相反——可能为开发有效的HCV疫苗提供一条替代途径。